Sunday Science Testosterone 2026_04_19
- laartzy
- Apr 20
- 1 min read
Sunday Science Testosterone 2026_04_19
Sunday Science: Testosterone Therapy – Risks, Benefits & Longevity Debate
Summary by Speaker
Dr. Brent Laartz
Discusses testosterone decline with age (0.4-2.6%/year, 30-50% by 50-60), low T (<250-300 ng/dL) linked to metabolic syndrome, obesity, increased mortality.
Reviews studies:- Low T associated with 1.5-2.3x higher all-cause, CV, cancer mortality (2010 European Heart Journal cohort; 2011 JCEM meta-analysis).- Frailty mediates 35% of low T mortality risk.- Eunuch/castration studies (Korea, Poland, animals): 10-20% longer lifespan, but pre-puberty vs. late-life low T.- TRT studies: Decreased mortality if levels normalized (2012, 2015 European Heart Journal cohorts); short-term (<2-9 months) neutral/possible risk, long-term (>3 years) benefit; non-normalized TRT no benefit.
Notes biases in cohorts (healthy user effect); no RCTs yet.
Emphasizes N=1 individualized approach considering personal risks (e.g., prostate/heart disease).
Key Points and Decisions
Low Endogenous Testosterone: Strongly linked to higher mortality (all-cause, CV, cancer); associated with frailty, metabolic issues.
Castration/Eunuch Data: Suggests lifelong low T may extend life, but not directly comparable to adult TRT.
TRT Evidence: Cohort studies show mortality reduction with normalized levels (esp. long-term), but short-term CV risks possible; no definitive RCTs.
No Firm Decisions: Informational only; no endorsements for/against TRT; highlights need for RCTs to resolve controversy.
Next Steps
Research: Await randomized controlled trials (RCTs) for definitive TRT mortality data.
Individuals: Check testosterone/health markers regularly (yearly+); consult physicians for personalized risks/benefits; prioritize resistance training, healthy lifestyle.
Audience: Seek professional medical advice; follow show on YouTube, Spotify, Apple Podcasts, social media, goonpro.com.
Comments